©The Author(s) 2025.
World J Diabetes. Oct 15, 2025; 16(10): 109782
Published online Oct 15, 2025. doi: 10.4239/wjd.v16.i10.109782
Published online Oct 15, 2025. doi: 10.4239/wjd.v16.i10.109782
Figure 3 Rab5-mediated nephrin endocytosis by podocytes depends on Rab5 activation.
A and B: Co-immunoprecipitation of active Rab5 (Rab5-GTP) in podocytes after different treatments and quantification of these results (n = 3); C and D: Representative co-localization images and quantitative of nephrin (green) and active Rab5 (red) in podocytes after different treatments (magnification: × 630; Scale bar: 20 μm); E and F: Co-immunoprecipitation of nephrin and active Rab5 in podocytes after different treatments and quantification of these results (n = 3); G and H: Western blot analysis of cytoplasmic nephrin and total nephrin in podocytes after different treatments and quantification of the C-nephrin/T-nephrin ratio (n = 3). aP < 0.05; bP < 0.001. HG: High-dose glucose.
- Citation: Zha DQ, Gao P, Wu XY. Nicotinamide mononucleotide protects against diabetic nephropathy via IL-6/Rab5-mediated crosstalk between proximal tubular epithelial cells and podocytes. World J Diabetes 2025; 16(10): 109782
- URL: https://www.wjgnet.com/1948-9358/full/v16/i10/109782.htm
- DOI: https://dx.doi.org/10.4239/wjd.v16.i10.109782